Headline News
Thursday, December 1, 2005
Category University/Hospitals
Moms Who Breastfeed May Be Protected From Type 2 Diabetes
BOSTON—The American Academy of Pediatrics recommends that mothers breastfeed infants for at least a year to help a baby’s growth, development and overall health. Now a study from Brigham and Women’s Hospital (BWH) has found benefits for mothers as well.
Dendritic Cells Offer New Therapeutic Target For Drugs To Treat Ms And Other Autoimmune Disease
November 29, 2005 -- Scientists at the Johns Hopkins Kimmel Cancer Center have found that a gene pathway linked to a deadly form of leukemia may provide a new way to treat autoimmune diseases, including multiple sclerosis.
Young Women Who Smoke Prior to Their First Pregnancy Have a Higher Risk of Breast Cancer in Their Later Years
November 30, 2005 | ROCHESTER, Minn. -- Researchers outline in the November issue of Mayo Clinic Proceedings their study of postmenopausal women, which supports the hypothesis that women who smoke cigarettes before first full-term pregnancy have a 20 percent increased risk of bre ast cancer compared with women who began smoking after the birth of their first child or were never smokers.
MUHC and McGill scientists identify gene for debilitating vitamin B12 disease
November 30, 2005 -- Scientists at the MUHC and McGill University have identified a gene responsible for a disease that impairs the body's ability to handle vitamin B12 and that may contribute to heart disease, stroke and dementia.
Hormone aldosterone is promising target for stroke treatment
Nov. 30, 2005 -- A bi-polar hormone that can contribute to strokes and minimize their damage is emerging as a therapeutic target in the battle against these brain attacks, researchers say.
Ancient Healing Herb Improves Alzheimer's Symptoms
November 29, 2005 | PORTLAND, Ore. - An herb traditionally used in the ancient Hindu system of healing known as Ayurveda improved memory in a mouse model for Alzheimer's disease, Oregon Health & Science University researchers have found.
OHSU Research Findings Contradict Longstanding Bias Against The Use Of Morphine At The End Of Life
November 30, 2005 | PORTLAND, Ore. - A report written by an OHSU physician with more than a half century of medical experience contradicts both public and professional bias against the use of morphine in the final stage of life for patients with breathing difficulties.
How eating (and growing) could improve your IQ
30 November 2005 -- The connection between childhood growth and levels of intelligence is explored in a new study from the Children of the 90s project.
Poxvirus used to fight cancer
November 16, 2005-- A cross-Canada scientific collaboration has successfully tested a potent new cancer-fighting virus that eliminates malignant brain tumours and prolongs survival in mice with a single injection.
Genetic key to growth of new arteries is identified
30 November 2005 -- Researchers at the San Francisco VA Medical Center have uncovered part of the genetic mechanism that causes new arteries to grow in response to blocked arteries.
Study hints at role of stem cell genes in testicular, breast cancers
29 November 2005 -- UCSF scientists have discovered that the activity of several embryonic stem cell genes is elevated in testicular and breast cancers, providing some of the first molecular evidence of a link between embryonic stem cells and cancer.
Tiny cellular structure plays big role in mammalian gene regulation
November 30, 2005. | GAINESVILLE, Fla. — University of Florida researchers have discovered a new ingredient in our cellular soup, tiny structures that may lay the groundwork for how new cells form and then function.
Radiation treatment prolonged liver cancer patients’ lives, U-M study finds
November 29, 2005 | ANN ARBOR, MI – Surgery is the most effective way to treat tumors that grow in the liver. But for most patients, the tumor is growing in a way that it can't be removed. And when that happens, few options remain.
Creativity determines sexual success
30 November 2005 -- The more creative a person is, the more sexual partners they are likely to have, according to a pioneering study which could explain the behaviour of notorious womanisers such as poets Lord Byron and Dylan Thomas.
New research shows how evolution explains age of puberty
30 November 2005 -- This is the message of Professors Mark Hanson and Peter Gluckman, whose review of the evolution of puberty is published online this week in Trends in Endocrinology and Metabolism.
New antibody shows promise as cure for anthrax
November 29, 2005 | AUSTIN, Texas -- A new anthrax antibody engineered by scientists at The University of Texas at Austin protects and defends against inhalation anthrax without the use of antibiotics and other more expensive antibodies.
Robotic treadmill training helps retrain brain, improves walking for some partially paralyzed people
DALLAS - Nov. 29, 2005 - People who have suffered partial paralysis from spinal-cord injury show increased activity in the part of the brain responsible for muscle movement and motor learning after 12 weeks of training on a robotic treadmill, researchers at UT Southwestern Medical Center have found.
Researchers use brain scans to predict behavior
Nov. 29, 2005 — By peering into the minds of volunteers preparing to play a brief visual game, neuroscientists at Washington University School of Medicine in St. Louis have found they can predict whether the volunteers will succeed or fail at the game.
New Evidence Supports Century-Old Theory of Cancer Spread
November 30, 2005 | New Haven, Conn. — A Yale School of Medicine study in the December issue of The Lancet Oncology challenges mainstream oncology researchers to consider tumor cell hybridization with white blood cells as a major reason that cancer metastasizes or spreads to other parts of the body.
Category Professional Journals
Thyroid Condition Associated With Increased Heart Failure Risk Among Older Adults
CHICAGO—A hormonal condition known as subclinical hypothyroidism is associated with an increased risk of congestive heart failure among older adults, but not with other cardiovascular events and death, according to a study in the November 28 issue of the Archives of Internal Medicine, one of the JAMA/Archives journals.
Inflammatory Markers May Help Predict Stroke Risk In Middle-Aged People
CHICAGO—In addition to traditional risk factors such as diabetes, high blood pressure, age, and race, a particular enzyme and protein found in the blood may help identify middle-aged men and women at increased risk for ischemic stroke, according to a study in the November 28 issue of the Archives of Internal Medicine, one of the JAMA/Archives journals.
Category Professional Associations
AAAAI, ACAAI identify new recommendations for sinusitis diagnosis and managementfrom the Journal of Allergy & Clinical Immunology
November 29, 2005 | MILWAUKEE - Sinusitis is one of the most diagnosed diseases in the United States, affecting approximately 16% of the adult population, and is responsible for nearly $5.8 billion in health care costs annually, according to an updated practice parameter.
Category Pharmaceutical Companies
Number of pills affects adherence to HIV treatment regimens
Research Triangle Park, NC – November 30, 2005 – Fixed-dose combination therapies for HIV may increase the likelihood of treatment adherence among patients, according to a recently published study of 2,112 patients conducted by GlaxoSmithKline.
New Drug Application Submitted for Potential New Treatment for Schizophrenia
Titusville, NJ (November 30, 2005) – Johnson & Johnson Pharmaceutical Research & Development, LLC, announced that it has submitted a New Drug Application to the United States Food and Drug Administration (FDA) for Paliperidone Extended-Release (ER) Tablets, an investigational extended-release, once daily, oral medication for the treatment of schizophrenia.
U.S. Patent Office to Issue Decision Confirming Validity of Pfizer's Crystalline Patent for Lipitor
NEW YORK, November 29 -- Pfizer Inc said today that the U.S. Patent and Trademark Office (USPTO) has announced that it will confirm the validity of Pfizer's U.S. patent covering the crystalline form of atorvastatin calcium used as the active ingredient in the cholesterol-lowering medicine Lipitor.
Ranbaxy Launches Two New Anti-HIV Products In India On World Aids Day
Gurgaon, India, November 30, 2005 -- Ranbaxy Laboratories Limited (RLL) announced today that the Company is introducing two new anti-HIV products, Virolis-E and Virocomb-E, in India. Both products contain three Anti Retroviral drugs each and offer WHO recommended first line Highly Active Anti Retroviral Therapy (HAART) in convenient daily use packs.
Roche and BioCryst collaborate on clinical compound BCX-4208 for transplantation and autoimmune diseases
Basel, 30 November 2005 -- Roche and BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced an exclusive license to develop and commercialize BioCryst’s phase I compound, BCX-4208, for the prevention of acute rejection in transplantation and for the treatment of autoimmune diseases. BCX-4208 is believed to have a potent ability to modulate T-cell activity.
Schering announces start of three Phase II clinical trials with anti-cancer compound ZK-EPO
November 30, 2005 -- Schering AG, Germany (FSE: SCH, NYSE: SHR) today announced the start of three Phase II studies in Europe evaluating its fully synthetic epothilone, ZK-EPO, for the treatment of several types of cancers such as non-small cell lung cancer, ovarian cancer and breast cancer.
FDA Approves New Indication for AVELOX(R) (moxifloxacin HCl) for Treatment of Complicated Intra-Abdominal Infections (cIAI)
KENILWORTH, N.J., Nov. 30 -- Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved the once-daily, broad-spectrum antibiotic AVELOX(R) (moxifloxacin HCl) for a new use -- the treatment of complicated intra-abdominal infections (cIAI) in adults. AVELOX is the only marketed fluoroquinolone antibiotic approved by the FDA as monotherapy to treat this indication.
Homepage, please click here
About us, please click here
Registration, please click here
Unsubscribe, please click here or email at unsubscribe@healthorbit.ca
Further assistance, please email our Customer Service at cs@healthorbit.ca
This email contains both images and text messages. Images can only be best viewed only if your mail client supports HTML contents.Copyright © 2004 Health Orbit, Inc. All rights reserved.
Terms of UseCopyright and Intellectual PropertyDisclaimersPrivacy PolicySubscriber Agreement
|
|
||||
|
This Month
Month Archive
RSS Newsfeeds
Main Page RSS
|
Thursday, December 1
Headline News: Thursday, December 1, 2005
by
Alex Hsieh on behalf of Professor Henry Wang
on Thu 01 Dec 2005 06:52 PM AKST
A story of failure for World AIDS Day
by
Alex Hsieh on behalf of Professor Henry Wang
on Thu 01 Dec 2005 10:51 PM EST
World AIDS day traditionally_ has become an occasion for reciting statistics of a plague so_ overwhelming it remains_ beyond comprehension. But there was one AIDS day that was different_ and it was_ just two years ago.
Link to Article MSNBC.com
China making moves to stem the tide of AIDS
by
Alex Hsieh on behalf of Professor Henry Wang
on Thu 01 Dec 2005 10:49 PM EST
China is making moves to trying to stem the tide of AIDS among its more than 1.1 billion people with the goal of preventing the spread of AIDS to just 1.5 million as opposed to 10 million by the year 2010. NBC News Charles Hadlock reports.
Link to Article MSNBC.com
'A World Without AIDS'
by
Lyle
on Thu 01 Dec 2005 02:10 PM EST
After more than two decades, researchers say they are getting closer to developing an effective HIV/AIDS vaccine.
Link to Article MSNBC.com
Finally, a Healthy Reason for Fat?
by
Lyle
on Thu 01 Dec 2005 02:08 PM EST
A simple procedure to separate stem cells from fat -- and reinject them into a patient -- could mean big gains for tiny biotech Cytori
Link to Article BusinessWeek Online
U.S. Builds Stockpile of Vaccine for Flu Pandemic
by
Lyle
on Thu 01 Dec 2005 02:07 PM EST
By Justin Gillis
Washington Post The government expects to stockpile nearly 8 million doses of an experimental vaccine against pandemic influenza by February, and studies are underway that could stretch that supply to cover more than a third of the population, federal health experts said yesterday. Two manufacturers are already making doses of the experimental vaccine under contract, and most of them will be delivered to government stockpiles by late December, according to presentations made to an advisory panel of the Health and Human Services Department. That unusually rapid clip reflects the high priority the Bush administration has placed recently on preparing the nation for a catastrophic flu outbreak. The immediate plan is a start toward building a stockpile that eventually could reach tens of millions of doses, assuming that Congress appropriates enough money. In the worst case, scientists said, the vaccine being manufactured now would immunize only 4 million people, each of whom would need two shots a month apart. That means the vaccine would probably be restricted to critically needed personnel who would keep the government and public-safety services running during a pandemic. About a quarter of the vaccine is destined for a stockpile controlled by the Pentagon. A pandemic would be expected to confine millions of people to their homes for weeks or months, shutting down much of the economy. Techniques to dilute the vaccine while preserving a strong immune response are under study. In the most optimistic scenario, the stockpile due by February might be diluted to cover 120 million people out of a U.S. population of 298 million. Some preliminary research suggests that dilution will work, but scientists said larger studies are needed. How well the vaccine, diluted or not, would prevent influenza in a pandemic remains uncertain. "I didn't realize there was so much going on," said Charles M. Helms, a University of Iowa doctor and chairman of the National Vaccine Advisory Committee, which heard reports on the government's efforts at a meeting in Washington yesterday. "It's incredible." William Hall, a spokesman for the Health and Human Services Department, said the government has made it a point not to claim that vaccine dilution would produce a huge stockpile in the short run, since the studies needed to prove that are still underway. "We're trying to stretch the supply of vaccine, but to be perfectly honest, if a pandemic occurs tomorrow, we can cover 4 million people," he said. A fast-spreading form of influenza that sickens mostly birds but can also kill people has provoked worldwide alarm. So far the virus cannot jump readily from person to person. But scores of people, mostly in Asia, have caught it from birds, and it has killed half of them. Authorities fear that the virus will evolve to the point that it can spread readily in the human population. The influenza pandemic of 1918 killed perhaps 50 million people worldwide in months. President Bush announced a plan Nov. 1 to prepare the nation for a pandemic, and Congress is considering his request for more than $7 billion in emergency funds. There is no licensed human vaccine today, and standard vaccine against annual flu would offer little protection. Several countries, including the United States, are rushing to develop and stockpile a vaccine. The government also is stockpiling Tamiflu, a drug that might be used to treat infected people, but for prevention, a vaccine is the preferred approach. The effort is fraught with uncertainties, however. The experimental vaccine is designed to immunize people against the viral strain circulating in birds, but it is unclear how much protection it would provide if the virus evolved to spread readily among humans. Multiple human tests are underway, and Linda C. Lambert, chief of respiratory diseases at the National Institute of Allergy and Infectious Diseases, said researchers would offer some results soon. But scientists do not expect hard data on the number of deaths the vaccine could prevent to be available until a pandemic outbreak. Sanofi Pasteur SA of Lyon, France, and Chiron Corp. of Emeryville, Calif., are making the experimental vaccine under government contract. Several companies are working on more advanced vaccines that might offer strong protection with one shot, but those are years away. © 2004 The Washington Post Company |
Search
Links
|
||
